Ryan Kret

IBI363 plus bevacizumab extended progression-free survival vs docetaxel in patients with immunotherapy-resistant lung adenocarcinoma in a randomized phase 1b study.

The NMPA has accepted a supplemental application for subcutaneous toripalimab plus disitamab vedotin in first-line HER2-expressing urothelial carcinoma, following the May 2026 approval of the intravenous combination.

Petosemtamab plus pembrolizumab cut the risk of death by 50% in first-line PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma.

Updated ASTRO recommendations favor moderate hypofractionation for all risk groups and establish 5-fraction ultrahypofractionation as a standard option in localized prostate cancer.

The FDA received a BLA for etentamig in relapsed/refractory multiple myeloma, based on response and PFS gains in the phase 3 CERVINO trial.

Adjuvant pembrolizumab continued to extend DFS in resected stage IB to IIIA NSCLC, though OS did not differ from placebo.

Rinatabart sesutecan significantly improved PFS and OS vs investigator’s-choice chemotherapy in platinum-resistant ovarian cancer.

Adding LK101 to tislelizumab-based first-line maintenance yielded early antitumor activity and signs of immune activation in advanced NSCLC.

Surufatinib plus serplulimab and cisplatin/etoposide produced a 69.8% ORR in advanced extrapulmonary neuroendocrine carcinoma.

The FDA granted fast track designation to SBE303 for locally advanced or metastatic urothelial cancer previously treated with enfortumab vedotin.

Phase 1 data support continued investigation of roginolisib in advanced cancers, including metastatic uveal melanoma.

The European Commission approved pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, irrespective of cisplatin eligibility.

Andrea Cercek, MD, discusses the FDA approval of dostarlimab and its significance for dMMR locally advanced rectal cancer management.

Updated ARC-20 data showed casdatifan activity as monotherapy and in combinations across treatment lines in advanced clear cell RCC.

The FDA accepted an NDA for UGN-103 for recurrent low-grade intermediate-risk NMIBC, with a target action date of June 14, 2027.

Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.

Matthew P. Goetz, MD, explores menopausal status, recurrence risk, and adjuvant CDK4/6 inhibitor selection in HR-positive breast cancer.

First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.

Tenumomeran/raplemomeran plus pembrolizumab missed the PFS end point in HPV16-positive HNSCC.

Matthew P. Goetz, MD, explores first-line treatment selection, emerging targeted therapies, and unmet sequencing needs in metastatic breast cancer.

Omar Castaneda Puglianini, MD, discusses earlier CAR T-cell therapy use, sequencing with bispecific antibodies, and access barriers in multiple myeloma.

The FDA has granted fast track designation to opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer.

The FDA granted fast track designation to PSV359 for locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors.

The FDA granted fast track designation to the PSMA-targeted T-cell engager VIR-5500 for late-line metastatic castration-resistant prostate cancer.

Carotuximab plus apalutamide demonstrated longer median progression-free survival than apalutamide alone in an interim phase 2 analysis in mCRPC.

A randomized phase 2 trial of berzosertib plus carboplatin in pretreated mCRPC stopped for futility amid fewer responses and more high-grade toxicity than the control arm.

The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.

The 2026 amendment adds 40 new recommendations, including active surveillance, office-based treatment, and chemoablation for select recurrent low-grade disease.

Aglatimagene besadenovec plus EBRT was linked to a 41% lower risk of prostate cancer recurrence or death, alongside durable immune activity.

Japan approved Optune Pax plus gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer.